Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Isodiol International Inc ISOLF

Isodiol International Inc is a manufacturer and developer of phytoceutical consumer products using pharmaceutical and nutraceutical grade phytochemical compounds. It generates revenue from the sale of nutritional health products derived from hemp. Geographically, it derives a majority of revenue from the United States and also has a presence in Canada. Its product categories include Tinctures; Capsules; Topicals; Vape; Oral Spray; Skincare; and others.


GREY:ISOLF - Post by User

Bullboard Posts
Post by jb24on Dec 29, 2017 9:00am
97 Views
Post# 27244036

love those numbers

love those numbersSTATEMENTS OF OPERATIONS
(in C$) - YE Mar 31st 2017E 2018E 2019E 2020E 2021E 2022E 2023E 2024E 2025E
Revenue 24,240,524 60,732,280 94,135,034 145,909,302 186,034,360 237,193,809 302,422,107 385,588,186 491,624,938
COGS 12,120,262 30,366,140 47,067,517 72,954,651 93,017,180 118,596,905 151,211,053 192,794,093 245,812,469
Gross Profit 12,120,262 30,366,140 47,067,517 72,954,651 93,017,180 118,596,905 151,211,053 192,794,093 245,812,469
EXPENSES
SG&A 11,807,194 15,183,070 23,533,758 36,477,326 46,508,590 59,298,452 75,605,527 96,397,047 122,906,234
Shipping Costs 395,718 303,661 470,675 729,547 930,172 1,185,969 1,512,111 1,927,941 2,458,125
Share-based Compensation 1,934,344 1,214,646 1,882,701 2,918,186 3,720,687 4,743,876 6,048,442 7,711,764 9,832,499
Research & Development 18,292 19,207 20,167 21,175 22,234 23,346 24,513 25,739 27,026
EBITDA (2,035,286) 13,645,556 21,160,216 32,808,418 41,835,497 53,345,261 68,020,461 86,731,603 110,588,585
Depreciation
Amortization 106,246 155,045 324,036 459,229 567,383 653,907 723,125 778,500 822,800
EBIT (2,141,532) 13,490,511 20,836,179 32,349,189 41,268,114 52,691,355 67,297,336 85,953,103 109,765,785
Financing Costs 25,000 25,000 25,000 25,000 25,000 25,000 25,000 25,000 25,000
EBT (2,166,532) 13,465,511 20,811,179 32,324,189 41,243,114 52,666,355 67,272,336 85,928,103 109,740,785
Non-Recurring Expenses
Taxes 3,501,033 5,410,907 8,404,289 10,723,210 13,693,252 17,490,807 22,341,307 28,532,604
Net Profit (Loss) (2,166,532) 9,964,478 15,400,273 23,919,900 30,519,904 38,973,103 49,781,528 63,586,796 81,208,181
Source: FRC
gltals
Bullboard Posts